Tibet Aim Pharm. (SZ:002826) Shang Hai Zheng Quan Bao·2025-07-27 19:57Core Viewpoint - The announcement highlights the recent abnormal stock price fluctuations of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and the ongoing changes in control due to a share transfer agreement with Beijing Fuhai [2][3][4]. Group 1: Stock Trading Abnormalities - The stock of Tibet Yiming Xiya Pharmaceutical experienced a cumulative price deviation of over 20% across three consecutive trading days on July 23, 24, and 25, 2025, indicating abnormal trading activity [3]. - The company confirmed that there were no undisclosed significant matters affecting the stock price and that the operational environment remains stable [4][5]. Group 2: Share Transfer Agreement - On May 31, 2025, a share transfer agreement was signed between the controlling shareholder Gao Fan and Beijing Fuhai, involving the transfer of 43,855,883 shares, which represents 23.00% of the total shares of the company [4]. - A supplementary agreement to the share transfer was signed on July 25, 2025, with further details disclosed in a subsequent announcement [2][4]. Group 3: Compliance and Future Reporting - The company is awaiting compliance confirmation from the Shenzhen Stock Exchange regarding the share transfer and must complete the necessary procedures for share registration [5]. - The company plans to disclose its 2025 semi-annual report on August 15, 2025, and is currently preparing the financial data [5].